Triple negative breast cancer

A review of clinicopathologic characteristics and treatment options

Laura J. Porro, Amy A. Mrazek, Techksell M. Washington, Celia Chao

Research output: Contribution to journalArticle

Abstract

Breast cancer is the second leading cause of cancer death in women. Approximately 15-20% are triple negative breast cancer (TNBC: no protein expression of estrogen receptor, progesterone receptor, nor human epidermal growth factor receptor 2), representing one of the most challenging molecular subtypes of breast cancer. TNBC encompasses a heterogenous group of breast cancers that are not generally responsive to targeted therapies for hormone and growth factor receptors. Compared to their hormone receptor-positive counterparts, TNBC cases are associated with poor prognosis, worse overall survival and earlier recurrence. The purpose of this review is to describe the clinicopathologic features, molecular variants, associations with the BRCA genes, and therapeutic approaches for TNBC. New TNBC-targeted drug therapies are currently under investigation and include poly-ADP-ribose polymerase (PARP) inhibitors, platinum-based drugs, anti-epidermal growth factor receptor (EGFR) inhibitors, and anti-vascular endothelial growth factor receptor (VEGF) inhibitors. Both clinical trials and basic research are needed to further our understanding of the best treatment options for patients with TNBC.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalOpen Breast Cancer Journal
Volume6
Issue number1
StatePublished - May 12 2014

Fingerprint

Triple Negative Breast Neoplasms
Breast Neoplasms
Hormones
Vascular Endothelial Growth Factor Receptor
Growth Factor Receptors
Progesterone Receptors
Platinum
Epidermal Growth Factor Receptor
Cause of Death
Therapeutics
Clinical Trials
Recurrence
Drug Therapy
Survival
Research
Pharmaceutical Preparations
Genes
Neoplasms

Keywords

  • Triple negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Triple negative breast cancer : A review of clinicopathologic characteristics and treatment options. / Porro, Laura J.; Mrazek, Amy A.; Washington, Techksell M.; Chao, Celia.

In: Open Breast Cancer Journal, Vol. 6, No. 1, 12.05.2014, p. 1-8.

Research output: Contribution to journalArticle

Porro, Laura J. ; Mrazek, Amy A. ; Washington, Techksell M. ; Chao, Celia. / Triple negative breast cancer : A review of clinicopathologic characteristics and treatment options. In: Open Breast Cancer Journal. 2014 ; Vol. 6, No. 1. pp. 1-8.
@article{fb9b1c1a20974c72bc44496770f41063,
title = "Triple negative breast cancer: A review of clinicopathologic characteristics and treatment options",
abstract = "Breast cancer is the second leading cause of cancer death in women. Approximately 15-20{\%} are triple negative breast cancer (TNBC: no protein expression of estrogen receptor, progesterone receptor, nor human epidermal growth factor receptor 2), representing one of the most challenging molecular subtypes of breast cancer. TNBC encompasses a heterogenous group of breast cancers that are not generally responsive to targeted therapies for hormone and growth factor receptors. Compared to their hormone receptor-positive counterparts, TNBC cases are associated with poor prognosis, worse overall survival and earlier recurrence. The purpose of this review is to describe the clinicopathologic features, molecular variants, associations with the BRCA genes, and therapeutic approaches for TNBC. New TNBC-targeted drug therapies are currently under investigation and include poly-ADP-ribose polymerase (PARP) inhibitors, platinum-based drugs, anti-epidermal growth factor receptor (EGFR) inhibitors, and anti-vascular endothelial growth factor receptor (VEGF) inhibitors. Both clinical trials and basic research are needed to further our understanding of the best treatment options for patients with TNBC.",
keywords = "Triple negative breast cancer",
author = "Porro, {Laura J.} and Mrazek, {Amy A.} and Washington, {Techksell M.} and Celia Chao",
year = "2014",
month = "5",
day = "12",
language = "English (US)",
volume = "6",
pages = "1--8",
journal = "Open Breast Cancer Journal",
issn = "1876-8172",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Triple negative breast cancer

T2 - A review of clinicopathologic characteristics and treatment options

AU - Porro, Laura J.

AU - Mrazek, Amy A.

AU - Washington, Techksell M.

AU - Chao, Celia

PY - 2014/5/12

Y1 - 2014/5/12

N2 - Breast cancer is the second leading cause of cancer death in women. Approximately 15-20% are triple negative breast cancer (TNBC: no protein expression of estrogen receptor, progesterone receptor, nor human epidermal growth factor receptor 2), representing one of the most challenging molecular subtypes of breast cancer. TNBC encompasses a heterogenous group of breast cancers that are not generally responsive to targeted therapies for hormone and growth factor receptors. Compared to their hormone receptor-positive counterparts, TNBC cases are associated with poor prognosis, worse overall survival and earlier recurrence. The purpose of this review is to describe the clinicopathologic features, molecular variants, associations with the BRCA genes, and therapeutic approaches for TNBC. New TNBC-targeted drug therapies are currently under investigation and include poly-ADP-ribose polymerase (PARP) inhibitors, platinum-based drugs, anti-epidermal growth factor receptor (EGFR) inhibitors, and anti-vascular endothelial growth factor receptor (VEGF) inhibitors. Both clinical trials and basic research are needed to further our understanding of the best treatment options for patients with TNBC.

AB - Breast cancer is the second leading cause of cancer death in women. Approximately 15-20% are triple negative breast cancer (TNBC: no protein expression of estrogen receptor, progesterone receptor, nor human epidermal growth factor receptor 2), representing one of the most challenging molecular subtypes of breast cancer. TNBC encompasses a heterogenous group of breast cancers that are not generally responsive to targeted therapies for hormone and growth factor receptors. Compared to their hormone receptor-positive counterparts, TNBC cases are associated with poor prognosis, worse overall survival and earlier recurrence. The purpose of this review is to describe the clinicopathologic features, molecular variants, associations with the BRCA genes, and therapeutic approaches for TNBC. New TNBC-targeted drug therapies are currently under investigation and include poly-ADP-ribose polymerase (PARP) inhibitors, platinum-based drugs, anti-epidermal growth factor receptor (EGFR) inhibitors, and anti-vascular endothelial growth factor receptor (VEGF) inhibitors. Both clinical trials and basic research are needed to further our understanding of the best treatment options for patients with TNBC.

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84926321951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926321951&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1

EP - 8

JO - Open Breast Cancer Journal

JF - Open Breast Cancer Journal

SN - 1876-8172

IS - 1

ER -